Access the full text.
Sign up today, get DeepDyve free for 14 days.
Andrew Wolf, Elizabeth Fontham, T. Church, C. Flowers, Carmen Guerra, S. LaMonte, Ruth Etzioni, M. McKenna, K. Oeffinger, Y. Shih, L. Walter, Kimberly Andrews, O. Brawley, D. Brooks, S. Fedewa, Deana Manassaram-Baptiste, R. Siegel, R. Wender, Robert Smith (2018)
Colorectal cancer screening for average‐risk adults: 2018 guideline update from the American Cancer SocietyCA: A Cancer Journal for Clinicians, 68
Eric Montminy, Meijiao Zhou, L. Maniscalco, Wesal Abualkhair, M. Kim, R. Siegel, Xiao-Cheng Wu, S. Itzkowitz, J. Karlitz (2020)
Contributions of Adenocarcinoma and Carcinoid Tumors to Early-Onset Colorectal Cancer Incidence Rates in the United StatesAnnals of Internal Medicine, 174
A. Qaseem, C. Crandall, R. Mustafa, L. Hicks, T. Wilt (2019)
Screening for Colorectal Cancer in Asymptomatic Average-Risk Adults: A Guidance Statement From the American College of PhysiciansAnnals of Internal Medicine, 171
J. Lowery, D. Ahnen, P. Schroy, H. Hampel, N. Baxter, C. Boland, R. Burt, L. Butterly, M. Doerr, Mary Doroshenk, W. Feero, N. Henrikson, U. Ladabaum, D. Lieberman, E. McFarland, S. Peterson, Martha Raymond, N. Samadder, S. Syngal, T. Weber, A. Zauber, Robert Smith (2016)
Understanding the contribution of family history to colorectal cancer risk and its clinical implications: A state‐of‐the‐science reviewCancer, 122
Reiko Nishihara, K. Wu, P. Lochhead, Teppei Morikawa, X. Liao, Z. Qian, K. Inamura, S. Kim, A. Kuchiba, Mai Yamauchi, Yu Imamura, W. Willett, B. Rosner, C. Fuchs, E. Giovannucci, S. Ogino, A. Chan (2013)
Long-term colorectal-cancer incidence and mortality after lower endoscopy.The New England journal of medicine, 369 12
K. Bibbins-Domingo (2016)
Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement.Annals of internal medicine, 164 12
D. Joseph, J. King, Nicole Dowling, Cheryll Thomas, L. Richardson (2020)
Vital Signs: Colorectal Cancer Screening Test Use — United States, 2018Morbidity and Mortality Weekly Report, 69
C. Rutter, Eric Johnson, E. Feuer, Amy Knudsen, K. Kuntz, D. Schrag (2013)
Secular trends in colon and rectal cancer relative survival.Journal of the National Cancer Institute, 105 23
I. Lansdorp-Vogelaar, R. Gulati, A. Mariotto, C. Schechter, T. Carvalho, Amy Knudsen, N. Ravesteyn, E. Heijnsdijk, C. Pabiniak, M. Ballegooijen, C. Rutter, K. Kuntz, E. Feuer, Ruth Etzioni, H. Koning, A. Zauber, J. Mandelblatt (2014)
Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits.Annals of internal medicine, 161 2
D. Rex, C. Boland, J. Dominitz, F. Giardiello, David Johnson, T. Kaltenbach, T. Levin, D. Lieberman, D. Robertson (2017)
Colorectal cancer screening: Recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer.Gastrointestinal endoscopy, 86 1
Chyke Doubeni, A. Rustgi (2015)
Racial Disparities in Colorectal Cancer Survival: Is Elimination of Variation in Care the Cure?Journal of the National Cancer Institute, 107 10
Eric Miller, P. Pinsky, R. Schoen, P. Prorok, T. Church (2019)
Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: long-term follow-up of the randomised US PLCO cancer screening trial.The lancet. Gastroenterology & hepatology, 4 2
Chiu (2015)
3221Cancer, 121
Han-Mo Chiu, S. Chen, A. Yen, S. Chiu, J. Fann, Yi-Chia Lee, Shin-Liang Pan, Ming-Shiang Wu, C. Liao, Hsiu-Hsi Chen, S. Koong, S. Chiou (2015)
Effectiveness of fecal immunochemical testing in reducing colorectal cancer mortality from the One Million Taiwanese Screening ProgramCancer, 121
Jennifer Lin, L. Perdue, N. Henrikson, S. Bean, Paula Blasi (2021)
Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.JAMA, 325 19
C. Rutter, Amy Knudsen, Jennifer Lin, Kathryn Bouskill (2020)
Black and White Differences in Colorectal Cancer Screening and Screening Outcomes: A Narrative ReviewCancer Epidemiology, Biomarkers & Prevention, 30
Lowery (2016)
2633Cancer, 122
R. Siegel, S. Fedewa, W. Anderson, K. Miller, Jiemin Ma, P. Rosenberg, A. Jemal (2017)
Colorectal Cancer Incidence Patterns in the United States, 1974–2013Journal Of The National Cancer Institute, 109
T. Imperiale, D. Ransohoff, S. Itzkowitz, T. Levin, P. Lavin, G. Lidgard, D. Ahlquist, B. Berger (2014)
Multitarget stool DNA testing for colorectal-cancer screening.The New England journal of medicine, 370 14
Siegel (2021)
7CA Cancer J Clin, 71
A. Shaukat, Charles Kahi, C. Burke, L. Rabeneck, B. Sauer, D. Rex (2021)
ACG Clinical Guidelines: Colorectal Cancer Screening 2021.The American journal of gastroenterology, 116 3
Xabier Garca-Albniz, J. Hsu, M. Bretthauer, Miguel Hernn (2016)
Effectiveness of Screening Colonoscopy to Prevent Colorectal Cancer Among Medicare Beneficiaries Aged 70 to 79 YearsAnnals of Internal Medicine, 166
Virostko (2019)
3828Cancer, 125
John Virostko, A. Capasso, T. Yankeelov, B. Goodgame (2019)
Recent trends in the age at diagnosis of colorectal cancer in the US National Cancer Data Base, 2004‐2015Cancer, 125
R. Siegel, K. Miller, S. Fedewa, D. Ahnen, R. Meester, A. Barzi, A. Jemal (2017)
Colorectal cancer statistics, 2017CA: A Cancer Journal for Clinicians, 67
R. Siegel, K. Miller, Hannah Fuchs, A. Jemal (2021)
Cancer Statistics, 2021CA: A Cancer Journal for Clinicians, 71
Amy Knudsen, C. Rutter, Elisabeth Peterse, Anna Lietz, Claudia Seguin, R. Meester, L. Perdue, Jennifer Lin, R. Siegel, V. Doria-Rose, E. Feuer, A. Zauber, K. Kuntz, I. Lansdorp-Vogelaar (2021)
Colorectal Cancer Screening: An Updated Modeling Study for the US Preventive Services Task Force.JAMA, 325 19
G. Cooper, S. Markowitz, Zhengyi Chen, M. Tuck, J. Willis, B. Berger, D. Brenner, Li Li (2018)
Performance of multitarget stool DNA testing in African American patientsCancer, 124
O. Kronborg, O. Jørgensen, C. Fenger, M. Rasmussen (2004)
Randomized study of biennial screening with a faecal occult blood test: results after nine screening roundsScandinavian Journal of Gastroenterology, 39
J. Scholefield, S. Moss, C. Mangham, D. Whynes, J. Hardcastle (2011)
Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-upGut, 61
J. Faivre, V. Dancourt, C. Lejeune, M. Tazi, J. Lamour, Dominique Gerard, F. Dassonville, C. Bonithon‐Kopp (2004)
Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study.Gastroenterology, 126 7
ImportanceColorectal cancer is the third leading cause of cancer death for both men and women, with an estimated 52 980 persons in the US projected to die of colorectal cancer in 2021. Colorectal cancer is most frequently diagnosed among persons aged 65 to 74 years. It is estimated that 10.5% of new colorectal cancer cases occur in persons younger than 50 years. Incidence of colorectal cancer (specifically adenocarcinoma) in adults aged 40 to 49 years has increased by almost 15% from 2000-2002 to 2014-2016. In 2016, 26% of eligible adults in the US had never been screened for colorectal cancer and in 2018, 31% were not up to date with screening. ObjectiveTo update its 2016 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a systematic review to evaluate the benefits and harms of screening for colorectal cancer in adults 40 years or older. The review also examined whether these findings varied by age, sex, or race/ethnicity. In addition, as in 2016, the USPSTF commissioned a report from the Cancer Intervention and Surveillance Modeling Network Colorectal Cancer Working Group to provide information from comparative modeling on how estimated life-years gained, colorectal cancer cases averted, and colorectal cancer deaths averted vary by different starting and stopping ages for various screening strategies. PopulationAsymptomatic adults 45 years or older at average risk of colorectal cancer (ie, no prior diagnosis of colorectal cancer, adenomatous polyps, or inflammatory bowel disease; no personal diagnosis or family history of known genetic disorders that predispose them to a high lifetime risk of colorectal cancer [such as Lynch syndrome or familial adenomatous polyposis]). Evidence AssessmentThe USPSTF concludes with high certainty that screening for colorectal cancer in adults aged 50 to 75 years has substantial net benefit. The USPSTF concludes with moderate certainty that screening for colorectal cancer in adults aged 45 to 49 years has moderate net benefit. The USPSTF concludes with moderate certainty that screening for colorectal cancer in adults aged 76 to 85 years who have been previously screened has small net benefit. Adults who have never been screened for colorectal cancer are more likely to benefit. RecommendationThe USPSTF recommends screening for colorectal cancer in all adults aged 50 to 75 years. (A recommendation) The USPSTF recommends screening for colorectal cancer in adults aged 45 to 49 years. (B recommendation) The USPSTF recommends that clinicians selectively offer screening for colorectal cancer in adults aged 76 to 85 years. Evidence indicates that the net benefit of screening all persons in this age group is small. In determining whether this service is appropriate in individual cases, patients and clinicians should consider the patient’s overall health, prior screening history, and preferences. (C recommendation)
JAMA – American Medical Association
Published: May 18, 2021
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.